Cao X - Search Results

1

Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices.

Egloff SA, Cao X, Lachs R, Martin C, Mattlin M, Fennell E, Rayburn D, Schlauch D, Kurbegov D, Ide S, Battiwalla M. Egloff SA, et al. Among authors: cao x. Leuk Lymphoma. 2023 Dec;64(13):2101-2112. doi: 10.1080/10428194.2023.2254429. Epub 2023 Sep 7. Leuk Lymphoma. 2023. PMID: 37680012

2

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.

Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X. Stein EM, et al. Among authors: cao x. Leuk Lymphoma. 2021 Jun;62(6):1411-1421. doi: 10.1080/10428194.2020.1869959. Epub 2021 Jan 11. Leuk Lymphoma. 2021. PMID: 33430673

3

[No title available]

[No authors listed] [No authors listed] PMID: 36163964

4

[No title available]

[No authors listed] [No authors listed] PMID: 36163962

5

Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.

Shao C, Liu J, Zhou W, Raut MK, Monberg M, Cao X, Ricart AD, Balakumaran A. Shao C, et al. Among authors: cao x. Leuk Lymphoma. 2019 Apr;60(4):947-954. doi: 10.1080/10428194.2018.1508665. Epub 2018 Sep 20. Leuk Lymphoma. 2019. PMID: 30234407 Free article.

6

Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.

Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. Stein EM, et al. Among authors: cao x. J Med Econ. 2021 Jan-Dec;24(1):234-243. doi: 10.1080/13696998.2021.1876714. J Med Econ. 2021. PMID: 33472483 Free article.

7

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.

Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V. Atallah EL, et al. Among authors: cao x. Leuk Lymphoma. 2021 Jul;62(7):1730-1739. doi: 10.1080/10428194.2021.1885656. Epub 2021 Mar 1. Leuk Lymphoma. 2021. PMID: 33648418

8

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ. Cao X, et al. Clin Genitourin Cancer. 2020 Feb;18(1):e37-e45. doi: 10.1016/j.clgc.2019.10.010. Epub 2019 Oct 16. Clin Genitourin Cancer. 2020. PMID: 31727510

9

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.

Whitman ED, Liu FX, Cao X, Diede SJ, Haiderali A, Abernethy AP. Whitman ED, et al. Among authors: cao x. Future Oncol. 2019 Feb;15(5):459-471. doi: 10.2217/fon-2018-0620. Epub 2018 Sep 25. Future Oncol. 2019. PMID: 30251550 Free article.

10

Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.

McKay C, Burke T, Cao X, Abernethy AP, Carbone DP. McKay C, et al. Among authors: cao x. Clin Lung Cancer. 2016 Sep;17(5):449-460.e7. doi: 10.1016/j.cllc.2016.03.008. Epub 2016 Mar 29. Clin Lung Cancer. 2016. PMID: 27157534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,930 results

Search Page

Filters